kabutan

JCR Pharma, First Half Ordinary Profit Turns to Profit, Jul-Sep Ordinary Profit Turns to Profit

Thu Oct 30, 2025 2:00 pm JST Earnings

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Earnings Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced its financial results in the afternoon session on October 30th (14:00). The consolidated ordinary profit/loss for the cumulative second quarter of the fiscal year ending March 2026 (April to September) turned into a profit of 2.36 billion yen (compared to a loss of 1.62 billion yen in the same period last year). Progress toward the full-year plan of 2.40 billion yen was 98.4%, also surpassing the five-year average of 52.5%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the October to March period (second half) is expected to turn into a profit of 0.03 billion yen (compared to a loss of 5.85 billion yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit/loss turned to a profit of 3.11 billion yen (compared to a loss of 1.36 billion yen in the same period last year). The operating profit/loss margin drastically improved from -5.2% in the same period last year to 23.3%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 24,272 6,898 7,126 5,253 42.1 98.1 Oct 25, 2023 J-GAAP
Apr - Sep, 2024 16,657 -739 -1,621 -691 -5.5 ー Oct 30, 2024 J-GAAP
Apr - Sep, 2025 21,362 2,379 2,362 1,710 14.0 98.4 Oct 30, 2025 J-GAAP
YoY +28.2% － － － －

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 10 May 13, 2025 J-GAAP
Apr - Sep, 2025 Results 21,362 2,379 2,362 1,710 14.0 10 Oct 30, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 16,415 -5,911 -5,856 -4,068 -32.9 10 May 13, 2025 J-GAAP
Oct - Mar, 2025 Guidance 16,438 221 38 1,290 10.6 10 Oct 30, 2025 J-GAAP
YoY +0.1% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 42,871 7,531 7,264 5,507 44.1 20 May 10, 2024 J-GAAP
Mar, 2025 33,072 -6,650 -7,477 -4,759 -38.4 20 May 13, 2025 J-GAAP
Mar, 2026 Guidance 37,800 2,600 2,400 3,000 24.6 20 May 13, 2025 J-GAAP
YoY +14.3% － － － －

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 8,512 -443 -1,364 -892 -7.1 -5.2 Oct 30, 2024 J-GAAP
Oct - Dec, 2024 9,223 -15 241 115 0.9 -0.2 Jan 31, 2025 J-GAAP
Jan - Mar, 2025 7,192 -5,896 -6,097 -4,183 -33.8 -82.0 May 13, 2025 J-GAAP
Apr - Jun, 2025 8,569 -606 -749 -546 -4.5 -7.1 Jul 30, 2025 J-GAAP
Jul - Sep, 2025 12,793 2,985 3,111 2,256 18.5 23.3 Oct 30, 2025 J-GAAP
YoY +50.3% － － － －

Related Articles